Blog

According to MDLinx, Rofecoxib (Vioxx) — Merck’s blockbuster COX-2 selective anti-inflammatory drug — was withdrawn in 2004 after long-term clinical data revealed a significant increase in heart attack and stroke risk. This single mechanistic toxicology failure erased more than $30 billion in market value, triggered historic litigation, and permanently reshaped FDA’s cardiovascular risk requirements.

How Troglitazone’s Hepatotoxicity Changed Drug Development Forever — and Why It Still Matters Today Troglitazone (Rezulin), introduced by Warner-Lambert and later absorbed by Pfizer, was once celebrated as a breakthrough insulin-sensitizing therapy for type 2 diabetes. Within a few years, it became one of the most catastrophic toxicology failures in FDA history — linked to idiosyncratic yet sometimes fatal liver injury, multiple cases of acute liver failure, and a full U.S. market withdrawal in 2000.

According to The Hill, a widely used high-blood-pressure medication was voluntarily recalled after FDA testing identified contamination and quality issues that could pose serious risks to patients. https://thehill.com/policy/healthcare/5636604-high-blood-pressure-medication-voluntarily-recalled-fda Why do these recalls keep happening?  Because wherever chemistry, manufacturing, and patient exposure intersect — toxicology decides the outcome. Here’s the one idea you should take away: